CCR2 receptor blockade alters blood monocyte subpopulations but does not affect atherosclerotic lesions in apoE-/- mice

Atherosclerosis

Volumn 208, Issue 2, 2010, Pages 370-375

  Aiello, Robert J ^a   Perry, Bret D ^a   Bourassa, Patricia Ann ^a   Robertson, Andrew ^a   Weng, Weifan ^a   Knight, Delvin R ^a   Smith, Andrew H ^a   Frederick, Kosea S ^a   Kalgutkar, Amit ^a   Gladue, Ronald P ^a  

^a PFIZER INC   (United States)

Author keywords

Atherosclerosis; CCL2; CCR2; Ly 6C; Macrophages

Indexed keywords

APOLIPOPROTEIN E; CHEMOKINE RECEPTOR ANTAGONIST; CHEMOKINE RECEPTOR CCR2; CHEMOKINE RECEPTOR CCR2 ANTAGONIST; INCB 3344; MONOCYTE CHEMOTACTIC PROTEIN 1; PLACEBO; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ATHEROSCLEROSIS; BODY FAT DISTRIBUTION; CELL SUBPOPULATION; CONTROLLED STUDY; DRUG EFFICACY; EXPERIMENTAL MOUSE; IC 50; MALE; MIGRATION INHIBITION; MONOCYTE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RECEPTOR BLOCKING; TRANSGENIC MOUSE;

ANIMALS; ANTIGENS, LY; AORTIC VALVE; APOLIPOPROTEINS E; ATHEROSCLEROSIS; BONE MARROW TRANSPLANTATION; CHEMOKINE CCL2; MACACA FASCICULARIS; MACROPHAGES; MALE; MICE; MICE, TRANSGENIC; MODELS, BIOLOGICAL; MONOCYTES; RECEPTORS, CCR2;

EID: 74749090237     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2009.08.017     Document Type: Article

References (24)

1. Mantovani A. The chemokine system: redundancy for robust outputs. Immunol Today 20 (1999) 254-257
2. Zernecke A., Shagdarsuren E., and Weber C. Chemokines in atherosclerosis: an update. Arterioscler Thromb Vasc Biol 28 (2008) 1897-1908
3. Weber C., Zernecke A., and Libby P. The multifaceted contributions of leukocyte subsets to atherosclerosis: lessons from mouse models. Nat Rev Immunol 8 (2008) 802-815
4. Werle M., Schmal U., Hanna K., and Kruezer J. MCP-1 induces activation of MAP-kinases ERK, JNK and p38 MAPK in human endothelial cells. Cardiovasc Res 56 (2002) 284-292
5. Gu L., Okada Y., Clinton S.K., et al. Absence of monocyte chemoattractant protein-1 reduces atherosclerosis in low density lipoprotein receptor-deficient mice. Mol Cell 2 (1998) 275-281
6. Gosling J., Slaymaker S., Gu L., et al. MCP-1 deficiency reduces susceptibility to atherosclerosis in mice that overexpress human apolipoprotein B. J Clin Invest 103 (1999) 773-778
7. Aiello R., Bourassa P., Lindsey S., et al. Monocyte chemoattractant protein-1 accelerates atherosclerosis in apolipoprotein E deficient mice. Thromb Vasc Biol 19 (1999) 1518-1525
8. -/- mice reveals a role of chemokines in the initiation of atherosclerosis. Nature 394 (1998) 894-897
9. Guo J., Waard Vd, Eck M.v., et al. Repopulation of apolipoprotein E knockout mice with CCR2-deficient bone marrow progenitor cells does not inhibit ongoing atherosclerotic lesion development. Arterioscler Thromb Vasc Biol 25 (2005) 1014-1019
10. Osterud B., and Bjorklid E. Role of monocytes in atherogenesis. Physiol Rev 83 (2003) 1069-1112
11. Gordon S., and Taylor P.R. Monocyte and macrophage heterogeneity. Nat Rev Immunol 5 (2005) 953-964
12. hi monocytes dominate hypercholesterolemia-associated monocytosis and give rise to macrophages in atheromata. J Clin Invest 117 (2007) 195-205
13. Serbina N.V., and Pamer E.G. Monocyte emigration from bone marrow during bacterial infection requires signals mediated by chemokine receptor CCR2. Nat Immunol 7 (2006) 311-317
14. Brodmerkel C.M., Huber R., Covington M., et al. Discovery and pharmacological characterization of a novel rodent-active CCR2 antagonist, INCB3344. J Immunol 175 (2005) 5370-5378
15. Haringman J.J., Gerlag D.M., Smeets T.J.M., et al. A randomized controlled trial with an anti-CCL2 (anti-monocyte chemotactic protein 1) monoclonal antibody in patients with rheumatoid arthritis. Arthritis Rheum 54 (2006) 2387-2392
16. Bourassa P.K., Milos P.M., Gaynor B.J., Breslow J.L., and Aiello R.J. Estrogen reduces atherosclerotic lesion development in apolipoprotein E-deficient mice. Proc Natl Acad Sci USA 93 (1996) 10022-10027
17. Haghpassand M., Bourassa P.-A.K., Francone O.L., and Aiello R.J. Monocyte/macrophage expression of ABCA1 has minimal contribution to plasma HDL levels. J Clin Invest 108 (2001) 1315-1320
18. Doyon J., Coesemans E., Boeckx S., et al. Discovery of potent, orally bioavailable small-molecule inhibitors of hte human CCR2 receptor. ChemMedChem 3 (2008) 660-669
19. Fukuma N., Akimitsu N., Hamamoto H., et al. A role of the Duffy antigen for the maintenance of plasma chemokine concentrations. Biochem Biophys Res Commun 303 (2003) 137-139
20. lo monocytosis and almos abolishes atherosclerosis in hypercholesterolemic mice. Circulation (2008) 117
21. Furth R.v., and Sluiter W. Distribution of blood monocytes between a marginating and a circulating pool. J Exp Med 163 (1986) 474-479
22. Jimenez-Sainz M.C., Fast B., Federico Mayor J., and Aragay A.M. Signaling pathways for monocyte chemoattractant protein 1-mediated extracellular signal-regulated kinase activation. Mol Pharmacol 64 (2003) 773-782
23. Ashida N., Arai H., Yamasaki M., and Kita T. Distinct signaling pathways for MCP-1 dependent integrin activation and chemotaxis. J Biol Chem 276 (2001) 16555-16560
24. Ardigo D., Assimes T.L., Fortmann S.P., et al. Circulating chemokines accurately identify individuals with clinically significant atherosclerotic heart disease. Physiol Genom 31 (2007) 402-409